hydralazine has been researched along with ramipril in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Traub, O; Webb, RC | 1 |
| Berkenboom, G; Brékine, D; Fontaine, J; Grosfils, K; Staroukine, M; Unger, P | 1 |
| Lloyd, MC; Traub, O; Webb, RC | 1 |
| Böcker, W; Bruckschlegel, G; Grimm, D; Holmer, SR; Kromer, EP; Riegger, GA; Schunkert, H | 1 |
| El Salibi, E; Nguyen, T; Rouleau, JL | 1 |
| Hamilton, R; Lim, K; Prasad, GV; Vincent, L | 1 |
| Agodoa, LY; Appel, LJ; Bakris, GL; Charleston, J; Contreras, G; Gabbai, F; Greene, T; Hiremath, L; Jamerson, K; Kendrick, C; Kusek, JW; Lash, JP; Lea, J; Miller, ER; Phillips, RA; Rahman, M; Rostand, S; Toto, R; Wang, X; Wright, JT | 1 |
| Ayuzawa, N; Fujita, T; Ishizawa, K; Kawarazaki, W; Nagase, M; Takeuchi, M; Ueda, K; Yoshida, S | 1 |
| Carstens, JL; Kalluri, R; Korsten, P; Müller, GA; Steinle, U; Tampe, B; Tampe, D; Zeisberg, EM; Zeisberg, M | 1 |
1 review(s) available for hydralazine and ramipril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for hydralazine and ramipril
| Article | Year |
|---|---|
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diltiazem; Drug Administration Schedule; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Rate; Humans; Hydralazine; Hypertension; Male; Middle Aged; Ramipril; Renal Insufficiency, Chronic; Treatment Outcome | 2013 |
10 other study(ies) available for hydralazine and ramipril
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Angiotensin-converting enzyme inhibition during development alters calcium regulation in adult hypertensive rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Caffeine; Calcium; Calcium Channels; Cell Membrane; Disease Models, Animal; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Muscle Contraction; Muscle, Smooth, Vascular; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sarcoplasmic Reticulum | 1993 |
Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Arginine; Bradykinin; Cyclic GMP; Drug Synergism; Endothelium, Vascular; Hydralazine; Male; Nitric Oxide; omega-N-Methylarginine; Peptidyl-Dipeptidase A; Ramipril; Rats; Rats, Wistar; Vasodilation | 1995 |
Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Hydralazine; Hydrochlorothiazide; Hypertension; Linear Models; Muscle Contraction; Muscle, Smooth, Vascular; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vascular Resistance | 1995 |
Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Extracellular Matrix Proteins; Fibronectins; Gene Expression; Hydralazine; Hypertension; Hypertrophy, Left Ventricular; Laminin; Male; Procollagen; Ramipril; Rats; Rats, Wistar; RNA, Messenger; Transforming Growth Factor beta | 1998 |
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pacing, Artificial; Fibrosis; Heart Rate; Hemodynamics; Hydralazine; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Myocardium; Ramipril; Rats; Rats, Inbred SHR; Survival Analysis; Vasodilator Agents | 1998 |
Minimal change disease in association with fire coral (Millepora species) exposure.
Topics: Acute Kidney Injury; Animals; Anthozoa; Barbados; Bites and Stings; Combined Modality Therapy; Diving; Edema; Female; Forearm Injuries; Furosemide; Humans; Hydralazine; Intubation, Intratracheal; Labetalol; Marine Toxins; Middle Aged; Mitral Valve Insufficiency; Nephrosis, Lipoid; Nephrotic Syndrome; Prednisone; Pulmonary Edema; Ramipril | 2006 |
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
Topics: Albuminuria; Amides; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Cytoprotection; Disease Models, Animal; Disease Progression; Down-Regulation; Fumarates; Humans; Hydralazine; Hypertension; Kidney; Kidney Diseases; Mice; Mice, Transgenic; Ramipril; Renin; Renin-Angiotensin System; Sodium Chloride, Dietary; Time Factors | 2014 |
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.
Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Animals; CpG Islands; Dioxygenases; Disease Models, Animal; Disease Progression; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Fibroblasts; Fibrosis; GTPase-Activating Proteins; Humans; Hydralazine; Kidney; Mice; Mice, Inbred C57BL; Mice, Transgenic; Primary Cell Culture; Promoter Regions, Genetic; Proto-Oncogene Proteins; Ramipril; Renal Elimination; Renal Insufficiency, Chronic; Reperfusion Injury; Vasodilator Agents | 2017 |